Per-Protocol Versus Intention-to-Treat in Clinical Trials: The Example of GLOBAL-LEADERS Trial

Affiliations

Editorial

Carlos G Santos-Gallego et al. J Am Heart Assoc. 2022.

. 2022 May 17;11(10):e025561.

doi: 10.1161/JAHA.122.025561. Epub 2022 May 16.

¹ AtheroThrombosis Research Unit, Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY.

No abstract available

Keywords: Editorials; P2Y12 inhibitors; antiplatelet therapy; aspirin; clinical trial; intention‐to‐treat analysis.

Comment on

Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial.
Gragnano F, Zwahlen M, Vranckx P, Heg D, Schmidlin K, Hamm C, Steg PG, Gargiulo G, McFadden EP, Onuma Y, Chichareon P, Benit E, Möllmann H, Janssens L, Leonardi S, Zurakowski A, Arrivi A, Van Geuns RJ, Huber K, Slagboom T, Calabrò P, Serruys PW, Jüni P, Valgimigli M, Windecker S; GLOBAL LEADERS Investigators [Link]. Gragnano F, et al. J Am Heart Assoc. 2022 May 17;11(10):e024291. doi: 10.1161/JAHA.121.024291. Epub 2022 Mar 1. J Am Heart Assoc. 2022. PMID: 35229616 Free PMC article. Clinical Trial.

1. Santos‐Gallego CG, Badimon J. Overview of aspirin and platelet biology. Am J Cardiol. 2021;144(suppl 1):S2–S9. doi: 10.1016/j.amjcard.2020.12.018 - DOI - PubMed
1. Santos‐Gallego CG, Badimon J. Duration of antiplatelet therapy after complex PCI in the TWILIGHT‐COMPLEX trial: the Goldilocks dilemma. Cardiovasc Res. 2020;116:e93–395. doi: 10.1093/cvr/cvaa135 - DOI - PubMed
1. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug‐eluting stent: a multicentre, open‐label, randomised superiority trial. Lancet. 2018;392:940–949. doi: 10.1016/S0140-6736(18)31858-0 - DOI - PubMed
1. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, et al. Ticagrelor with or without aspirin in high‐risk patients after PCI. N Engl J Med. 2019;381:2032–2042. doi: 10.1056/NEJMoa1908419 - DOI - PubMed
1. Kim B‐K, Hong S‐J, Cho Y‐H, Yun KH, Kim YH, Suh Y, Cho JY, Her A‐Y, Cho S, Jeon DW, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323:2407–2416. doi: 10.1001/jama.2020.7580 - DOI - PMC - PubMed